Contents

Contributors xi

1 Antipsychotic treatment and adherence in schizophrenia 1
Chris Abbott and Sam Keith
  Introduction 1
  The course of schizophrenia 1
  Duration of untreated psychosis, relapse, and disease progression 2
  Antipsychotics and relapse prevention 3
  Antipsychotic treatment guidelines 5
  Defining adherence 6
  Measuring adherence 7
  Predictors of adherence 8
  Extent of poor adherence in schizophrenia 11
  Clinical consequences of non-adherence 11
  Economic consequences of non-adherence 12
  Interventions to improve medication adherence 13
  Summary and conclusions 14

2 Pharmacology of antipsychotic long-acting injections 23
Tim Lambert and David Taylor
  Introduction 23
  Overview of FGA-LAIs 23
  Overview of SGA-LAIs 24
  Kinetics: clinical applications 28
  Dosing equivalence 28
  Loading or initiation strategies 33
  Pharmacodynamics 37
  Switching to and from LAIs 39
  Conclusions 41

3 Adverse effects and antipsychotic long-acting injections 47
Peter Haddad and W. Wolfgang Fleischhacker
  Introduction 47
  Incidence of adverse effects with oral antipsychotics and LAIs 47
  Adverse effects secondary to poor adherence 53
Injection-related adverse effects  55
Injection-site complications and injection technique  59
Post-injection syndrome with OLAI  60
LAIs and time course of adverse effects  61
Cautions and contraindications to LAIs  63
Summary  64

4 First-generation antipsychotic long-acting injections  71
Mark Taylor and Polash Shajahan
Introduction  71
Review of FGA-LAIs in schizophrenia  72
Review of FGA-LAIs in bipolar disorder  80
Summary of evidence  85
Future research  87
Implications for clinical practice  87

5 Risperidone long-acting injection  93
Pierre Chue
Introduction  93
Oral risperidone  93
Pharmacokinetics of risperidone long-acting injection  94
Dosing of RLAI  95
Efficacy of RLAI  97
Risperidone long-acting injection and remission  102
Side-effects of RLAI  103
RLAI versus oral antipsychotics  107
RLAI versus FGA-LAIs  109
RLAI in early psychosis  110
RLAI in the elderly  111
RLAI in schizoaffective and bipolar disorder  112
Relationship of RLAI with functionality, patient satisfaction, insight, and health-related quality of life  114
RLAI and hospitalization data  115
RLAI and cost-effectiveness  117
Future research  119

6 Recently approved long-acting antipsychotic injections: paliperidone LAI and olanzapine LAI  131
John Lauriello and Niels Beck
Introduction: the case for additional long-acting agents  131
Paliperidone long-acting injection  132
Olanzapine long-acting injection  137
Conclusions  143
7 Long-acting injectable antipsychotics in early psychosis 145
Robin Emsley, Bonga Chiliza, Laila Asmal, and Mathias de Fleuriot

Introduction 145
Relapse and medication adherence 146
Partial adherence and partial response 147
Consequences of relapse and partial response 147
Antipsychotic LAIs 148
Rationale for using antipsychotic LAIs in the early stages of schizophrenia 148
Studies of FGA-LAIs in early psychosis 149
Studies of RLAI in early psychosis 150
Conclusions 158

8 Health professionals' and patients' attitudes to LAIs 163
Maxine X. Patel

Introduction 163
Psychiatrists' attitudes 163
Nurses' attitudes 167
Patients' attitudes 169
Implications 176
Conclusions 180

9 Patient choice and improving the uptake of long-acting injectable medication 185
Mary Jane Tacchi, Jennifer Nendick, and Jan Scott

Introduction 185
Patient choice 185
What happens when no choice is permitted? 186
Making choice work 187
Establishing the patient's model 188
The choice of long-acting injectable medication 190
Adherence with antipsychotic LAIs 191
Interventions to enhance medication adherence 192
Clinical techniques to improve adherence 200
Conclusions 203

10 Prescribing patterns and determinants of use of antipsychotic long-acting injections: an international perspective 209
Tim Lambert

Introduction 209
LAI prescription rates 210
Overview of influences on LAI prescription rates 216
Conclusion 230
11 The role of antipsychotic long-acting injections in current practice 241
   Peter Haddad, Tim Lambert, and John Lauriello
   Introduction 241
   Poor adherence and its consequences 241
   Advantages and disadvantages of LAIs 244
   LAIs and schizophrenia treatment guidelines 248
   When should an LAI be considered? 249
   Key issues and future research 251
   Summary and conclusions 255

Index 261